Back to Search
Start Over
652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC).
- Source :
-
Annals of Oncology . 2022 Supplement 7, Vol. 33, pS840-S840. 1p. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159077570
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.07.776